The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities - Scorecard - MDSpire

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

  • By

  • Zhennan Ma

  • Xiuqing Gong

  • Fuquan Liu

  • May 28, 2026

  • 0 min

Share

Clinical Scorecard: NAD+ Metabolic Reprogramming's Impact on Chemoresistance in Colorectal Cancer: Insights into Mechanisms and Clinical Implications

At a Glance

CategoryDetail
Condition
Key MechanismsNAD+ metabolic reprogramming regulates energy metabolism, DNA repair, and immune microenvironment, contributing to chemoresistance.
Target Population
Care Setting

Key Highlights

  • NAD+ metabolism is crucial for DNA repair and cell survival in CRC.
  • Key enzymes like NAMPT and SIRT1 are involved in sustaining NAD+ levels.

Guideline-Based Recommendations

Diagnosis

  • Evaluate NAD+ metabolic pathways in colorectal cancer patients.

Management

  • Consider NAD+ precursor supplementation and inhibitors of metabolic enzymes.

Monitoring & Follow-up

  • Implement monitoring technologies to assess NAD+ levels.

Risks

  • Tumor metabolic heterogeneity may impede clinical translation.

Patient & Prescribing Data

Patients with advanced colorectal cancer exhibiting chemoresistance.

Combination therapies targeting NAD+ metabolism show promise in overcoming resistance.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

    • by Zhennan Ma, Xiuqing Gong, Fuquan Liu

    • May 28, 2026

    Related Content

    Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

    Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

    Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant